# Dose-dependent, non-pigmenting fixed drug eruption with eczematous lesions induced by bosutinib: case report

## TL;DR

This case report describes a rare, dose-dependent non-pigmenting drug eruption caused by bosutinib, a leukemia treatment, and suggests dosage tapering as a management strategy.

## Contribution

The paper presents a unique case of dose-dependent non-pigmenting fixed drug eruption caused by bosutinib.

## Key findings

- Bosutinib can cause non-pigmenting fixed drug eruption in a dose-dependent manner.
- Tapering the drug dosage may help manage such eruptions when the drug is essential for treatment.

## Abstract

Bosutinib, widely used as a primary treatment for chronic myeloid leukemia (CML), is known to frequently cause cutaneous drug eruptions. Fixed Drug Eruption (FDE) is common, typically presenting as recurrent lesions that heal with residual hyperpigmentation. Diagnosing FDE, especially Non-Pigmenting Fixed Drug Eruption (NPFDE), is often challenging. A correlation exists between the dosage of certain medications, such as levetiracetam, and the emergence of drug eruptions. This report details a unique case of dose-dependent NPFDE caused by bosutinib. In managing cutaneous drug eruptions, particularly when the causative drug is crucial for treatment, a strategy of tapering the dosage should be considered.